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Abstract
Supratentorial ependymoma (ST-EPN) is a type of malignant brain tumor mainly seen in children. Since 2014, it has been
known that an intrachromosomal fusion C11orf95-RELA is an oncogenic driver in ST-EPN [Parker et al. Nature 506:451–455
(2014); Pietsch et al. Acta Neuropathol 127:609–611 (2014)] but the molecular mechanisms of oncogenesis are unclear.
Here we show that the C11orf95 component of the fusion protein dictates DNA binding activity while the RELA component
is required for driving the expression of ependymoma-associated genes. Epigenomic characterizations using ChIP-seq and
HiChIP approaches reveal that C11orf95-RELA modulates chromatin states and mediates chromatin interactions, leading to
transcriptional reprogramming in ependymoma cells. Our findings provide important characterization of the molecular underpinning of C11orf95-RELA fusion and shed light on potential therapeutic targets for C11orf95-RELA subtype ependymoma.
Keywords C11orf95-RELA · Supratentorial ependymoma · Transcription factor · 3D genome

Introduction
Ependymoma is the third most common malignant brain
tumor in children. It can be classified into three groups based
on location of the tumor: supratentorial, infratentorial and
spinal. Currently there is no effective chemotherapy identified and treatment is limited to surgery with or without
adjuvant radiation therapy. Because a significant portion of
ependymoma is found in young children, radiation therapy
is not desirable due to the detrimental effects on the developing brain. Thus, there is an urgent need to develop targeted
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s00401-020-02225-8) contains
supplementary material, which is available to authorized users.

therapy based on the underlying biology. C11orf95-RELA
fusion was found to be the most recurrent structural variation
in approximately 70% of supratentorial ependymomas (STEPN) [14, 15]. Neural stem cells transformed by C11orf95RELA were able to form brain tumor in mice [11, 14]. However, how C11orf95-RELA functions in tumorigenesis at
the molecular level is largely unknown. We present results
here showing that contrary to the hypothesis that C11orf95RELA ependymoma is driven by the RELA component of
the fusion, binding affinity of the fusion protein to DNA is
dictated by the C11orf95 component. The contribution of
the RELA component is to stabilize the DNA binding of
the fusion protein and provide its activation domain to drive
expression of the target genes.
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Materials and methods
Cell culture
HEK293T and its derived G16-2, G16-3, G16-4 cells as
well as BXD-1425-EPN cells were cultured in Dulbecco’s
modified Eagle’s medium (Sigma) with 10% fetal bovine
serum (Lonza), 4% Glutamax (Gibco), 1% sodium pyruvate
(Gibco) and penicillin–streptomycin (Gibco). Incubator conditions were 37 °C and 5% C
 O2. Protein overexpression in
G16-2, G16-3 and G16-4 cells were induced by 1 μg/ml
doxycycline treatment for 2 days.

Virus production
A viral packaging mix of pLP1, pLP2, and VSV-G were
co-transfected with each lentiviral vector (pCW-RELA-HA,
pCW-C11orf95fus1-HA, or pCW-C11orf95-RELAfus1-HA)
into Lenti-X 293T cells (Clontech), seeded the day before
in 6-well plates at a concentration of 1.2 × 106 cells per
well, using Lipofectamine 3000 (ThermoFisher). Media
was changed 6 h after transfection then incubated overnight.
Twenty-eight hours post transfection, the media supernatant
containing virus was filtered using 45 μm PES filters then
stored at − 80 °C until use.

50661), and pmax-DEST (transient constitutive expression,
Addgene # 48222) vectors, generating pCW-C11orf95fus1HA, or pCW-C11orf95-RELAfus1-HA, pCW-RELA-HA lentiviral Dox-inducible plasmids and pmax-C11orf95fus1-HA,
pmax-C11orf95-RELAfus1-HA, pmax-RELA-HA transient
expression plasmids. pmax-Clover and pmax-C11orf95Clover, and pmax-C11orf95 fus1-VP64, pmax-mScarletH2A, plasmids were generated with a combination of PCR,
restriction-ligation, SLIC and LR Clonase II reactions.
GFP-reporter plasmids, 15xUSF1-minCMV-EGFP and
15xC11orf95-minCMV-EGFP, were generated by ligation of
annealed oligos containing USF1 or C11orf95 binding sites
into minCMV-EGFP plasmid with non-palindromic overhang sites via digestion with BsaI, subsequently screened for
the number of binding sites by Sanger sequencing.

Transfection and imaging
Cells were seeded into 12-well plates at a density of
1.5 × 105 cells per well the day before transfection. For
imaging experiments, 300 ng of pmax-C11orf95fus1-Clover
or pmax-Clover (unfused control) was co-transfected with
100 ng of pmax-mScarlet-H2A (nuclear marker) using 1.5
µL Attractene transfection reagent (Qiagen). Microscopy
images were taken with the iRiS Digital Cell Imaging System (Logos Biosystems).

Cell line generation

Flow cytometry

To make G16-2, G16-3, and G16-4 cell lines, the day prior
to transduction, HEK293T cells were seeded into 12-well
plates at a density of 1.5 × 105 cells per well. Prior to transduction, media was changed to that containing 10 μg/ml
polybrene, 1 ml per well. 250 μl of each respective virus
was added to each well and incubated overnight. Media was
changed 24 h post-transduction. Four days post-transduction, cells were split. Five days post-transduction, media
with antibiotics (2 μg/ml Puromycin) was added to each
respective well of one replicate plate. Antibiotic selection
continued for at least 2 weeks before use in downstream
experiments.

GFP-reporter plasmid DNA (300 ng) containing 15xUSF1
binding sites (15xUSF1-minCMV-EGFP) or 15xC11orf95
binding sites (15xC11orf95-minCMV-EGFP) was co-transfected with 300 ng of plasmid expressing test transcription
factor constructs (EmptyVector, pmax-C11orf95fus1, pmaxC11orf95-RELA fus1, pmax-RELA, pmax-C11orf95fus1VP64) using 1.5 µl Lipofectamine 3000 (ThermoFisher).
48 h after transfection, cells were trypsinized, suspended in
media then analyzed on a LSRFortessa X-20 flow cytometer
(BD Bioscience). Fifty thousand events were collected each
run.

Cloning
fus1

ORF encoding C11orf95
was obtained as IDT gBlock
while HEK293T cDNA served as template for amplifying
RELA sequence. PCR and SLIC cloning were used to insert
ORF encoding C
 11orf95fus1, C11orf95-RELAfus1, RELA
with C-terminal HA tag into Gateway donor vector (pCR8/
GW/TOPO, Invitrogen). Then LR clonase II reactions were
used to shuttle ORFs into pCW-DEST (lentiviral Doxinducible expression) derived from pCW-Cas9 (Addgene #
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Western blot
Western blot was performed using general protocol from
Bio-Rad. Primary antibodies used were HA antibody (Cell
Signaling Technology 3724S), RELA antibody (Abcam
ab32536), and β-actin antibody (Cell Signaling Technology
4970S).

Genotyping
BXD-1425-EPN DNA was extracted using DNeasy Blood
& Tissue Kit (Qiagen), followed by genotyping PCR using
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Phusion PCR protocol (NEB) with primer pair of forward:
CCTGCACCTGGACGACAT and reverse: TTGGTGGTA
TCTGTGCTCCTC. PCR amplicons were sent for Sanger
sequencing, and analyzed by ApE.

Gene ontology analysis
Gene ontology analysis was done with Metascape (https://
metascape.org/).

DNA motif analysis
ChIP-seq peak sequences were uploaded and analyzed by
MEME-ChIP (https://meme-suite.org/tools/meme-chip).
Motifs were found de novo by DREAM. Sequences that had
specific motif were reported by FIMO.

RNA‑seq and analysis
RNA was extracted using RNeasy Mini Kit (Qiagen), then
sent to Genewiz for library construction and sequencing by
Illumina Nextseq sequencer. Each sample had two biological
replicates. RNA-seq data was quantified using Salmon (version 0.8.0), followed by differential expression analysis using
DEseq2. The cutoff for identifying differentially expressed
genes were set as FDR < 0.05 and fold change ≥ 1.5.

ChIP‑seq and analysis
ChIP was performed using iDeal ChIP-seq kit for Transcription Factors (Diagenode) and protocol provided. HA (Cell
Signaling Technology 3724S), RELA (Abcam ab32536)
and H3K27ac (Cell Signaling Technology 8173S) antibodies were used for chromatin pull-down. Libraries were constructed using KAPA Hyper Prep Kits (Roche) and NEBNext® Multiplex Oligos for Illumina® (NEB) for Illumina
Nextseq sequencing. Each sample had two biological replicates. The reproducibility between replicates was evaluated by Pearson correlation coefficient of read counts using
deepTools (version 3.3.0) which was all greater than 0.95.
Replicates were then combined for peak calling.
Sequencing data was mapped to hg38 reference genome
by Bowtie2 (version 2.3.1). Sequences with mapping quality
score greater than ten were accepted for the following analysis. Peaks were called by MACS2 (version 2.1.0.20151222)
using “–q 0.01 –nomodel –extsize 200” parameter for
transcription factor ChIP-seq, and using “–broad −q 0.05,
–nomodel –extsize 220” for histone mark ChIP-seq. For
peaks that had at least 1 bp overlap, we considered them
as overlapped peaks. The peak was considered to locate at
gene promoter when it had at least 1 bp overlap with the
promoter region. Promoter region was defined as a 5 kb
span extending 2.5 kb at both sides from the transcription
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start site (TSS). Differential H3K27ac peaks were called
by MACS2 bdgdiff subcommand. Read density heatmap of
ChIP-seq peaks were computed and plotted using deepTools
(version 3.3.0). Data was viewed by Integrative Genomics
Viewer (IGV).

HiChIP and analysis
HiChIP was performed following protocol published by
Mumbach et al. 2017, with minor modifications. HA (Cell
Signaling Technology 3724S) and H3K27ac (Cell Signaling Technology 8173S) antibodies were used for chromatin
pull-down. Libraries were constructed using KAPA Hyper
Prep Kits (Roche) and NEBNext® Multiplex Oligos for
Illumina® (NEB) for Illumina Novaseq sequencing. Each
sample had two biological replicates. Replicate data was
combined for analysis. Raw data was processed by HiC-Pro
[17] using hg38 reference genome. Chromatin interactions
were called using hichipper [6] by providing certain ChIPseq peaks and HiC-Pro outputs. Interaction heatmap was
plotted by HiCPlotter [1] at 10 kb resolution. Interactions
associated with specific genes were filtered by interaction
count greater than one, then visualized on WashU Epigenome Browser, or processed for enhancer-promoter analysis.

Canonical pathway analysis
Canonical pathway analysis was done by Ingenuity Pathway
Analysis (IPA) using “Core Analysis” function.

Results
C11orf95‑RELA is a novel transcription factor
that recognizes a specific DNA motif dictated
by the C11orf95 fragment
C11orf95-RELAfus1 was identified as the most frequently
occurring fusion subtype in supratentorial ependymoma
with C11orf95-RELA fusion (ST-EPN-RELA), containing
almost the entire RELA gene except the first two codons
fused to a truncated C11orf95 gene fragment (C11orf95fus1)
harboring two and a half exons out of five exons of the fullsize gene [14]. Unlike RELA, which is a well-known transcription factor subunit of NF-κB, C11orf95 is an uncharacterized protein. While nuclear localization of RELA is
dependent on NF-κB activation, C11orf95-RELA fusion
protein is constitutively localized in the nucleus in transformed HEK293T and mouse neural stem cells [14]. Intriguingly, C11orf95fus1 contains a C2H2 zinc finger domain typically found in transcription factors (Supplementary Fig. 1,
online resource), implying its DNA binding potential. We
hypothesized that the fusion of C11orf95 and RELA create
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a novel transcription factor whose DNA binding affinity
as well as nuclear localization are largely governed by the
C11orf95 fragment. Interestingly, fusion of C11orf95fus1
fragment to GFP is sufficient to drive exclusive localization of the fluorescence signal in the nucleus of HEK293T
cells, demonstrating the intrinsic propensity of the C11orf95
fus1
fragment to translocate into the nucleus (Supplementary Fig. 2, online resource). However, there was previously no direct evidence for the binding of C11orf95fus1 and
C11orf95-RELAfus1 to DNA. To address this question and
further decipher the regulatory mechanisms of the fusion
protein, we engineered HEK293T cell lines to express
C11orf95-RELAfus1 (G16-4), C11orf95fus1 fragment (G163), or the RELA fragment (G16-2) in order to study the
contribution of the fusion protein and each of the partners
to epigenetic program and transcriptional regulation. These
transgenes are tagged with the HA-epitope and are under the
control of a doxycycline-inducible TetO promoter (Supplementary Fig. 3a, b, online resource). The HA tag facilitates
our molecular experimentations such as Western blot and
ChIP, despite the lack of good quality antibodies against
the fusion and C11orf95 proteins. We then conducted ChIPseq using HA antibody to profile genome-wide chromatin
bindings of RELA, C
 11orf95fus1 and C11orf95-RELAfus1

in G16-2, G16-3 and G16-4 cells, respectively. Surprisingly, 32,152 and 38,428 binding peaks were identified for
C11orf95-RELAfus1 and C11orf95fus1, respectively, with
16,829 overlapping (Fig. 1a). In contrast, RELA ChIPseq only identified 111 binding sites in total. Considering
RELA is normally inactive without cellular stimulation, we
treated G16-2 cells with tumor necrosis factor (TNF) for
six hours after doxycycline induction of RELA expression,
in order to capture RELA bindings in its active state. As a
result, 1542 binding peaks were identified, which was still
far fewer than the binding peaks identified for the fusion or
C11orf95. Among the RELA binding peaks identified in the
presence of TNF stimulation, less than 25% overlapped with
C11orf95-RELAfus1 peaks (Fig. 1a). These results indicate
that C11orf95fus1 contributes to the majority of DNA binding of the fusion protein.
Although both C11orf95fus1 and C11orf95-RELAfus1
can bind to DNA, their binding targets were not completely identical. Other than the common peaks, there were
also specific peaks for each of the two proteins (Fig. 1a).
Among the 16,829 shared peaks, C11orf95-RELAfus1 had
significantly higher signal densities than C
 11orf95fus1 after
sequencing read normalization (Fig. 1b), suggesting the
RELA portion of the fusion protein might stabilize DNA

Fig. 1  a Venn diagram of ChIP-seq peaks. The DNA pull-down were
done by RELA-HA (blue, the smallest circle) in G16-2 cells, RELAHA after TNF treatment (magenta) in G16-2 cells, C11orf95fus1-HA
(green) in G16-3 cells and C11orf95-RELAfus1-HA (red) in G16-4
cells. The numbers indicate the total peaks identified in each cohort.
The Venn diagram is not dawn to scale. b Read densities over ChIPseq peaks of C
 11orf95fus1 and C11orf95-RELAfus1. Using peak sum-

mit as the center, the normalized mapped reads over a 1 kb region
around the peak were plotted for a total of 16,829 shared peaks of
C11orf95fus1 and C11orf95-RELAfus1. c Gene ontology analysis
on C11orf95fus1 and C11orf95-RELAfus1 common binding genes,
C11orf95fus1 unique binding genes and C11orf95-RELAfus1 unique
binding genes. The top three ranked biological processes according to
q value are shown
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binding. Furthermore, we selected genes that were bound by
C11orf95fus1 and/or C11orf95-RELAfus1 at promoter regions,
categorized them into three groups: C
 11orf95 fus1 and
fus1
C11orf95-RELA
common binding genes, C
 11orf95fus1
fus1
unique binding genes and C11orf95-RELA unique binding genes. Gene ontology (GO) analysis showed C11orf95RELAfus1 unique binding genes were specifically enriched
in neuron projection morphogenesis, actin filament process
and skeletal system morphogenesis, which are known to
be associated with brain or brain disease development [3,
7, 16, 18]. C11orf95fus1 and C11orf95-RELAfus1 common
binding genes were enriched in cell cycle arrest, regulation
of autophagy and regulation of mitochondrion organization. However, C
 11orf95fus1 unique binding genes were
enriched in more fundamental biological processes such
as translation, carbohydrate derivative biosynthetic process and asparagine N-linked glycosylation (Fig. 1c, Supplementary Table 1, online resource). In addition, we also
obtained gene expression profiles of G16-3 and G16-4, as
well as HEK293T control cells by RNA-seq to interrogate
the transcriptional effects of C
 11orf95fus1 and C11orf95fus1
RELA . Sixty-six and 210 genes were identified to be
up-regulated (FDR < 0.05, fold change ≥ 1.5) in G16-3 and
G16-4 cells, respectively, compared to the controls. In parallel, we compiled a list of 886 ST-EPN-RELA-associated
genes (Supplementary Table 2, online resource) based on
published data [13, 14, 19]. By comparing G16-3 and G16-4
up-regulated genes to ST-EPN-RELA-associated genes, only
three of G16-3 ( C11orf95fus1) up-regulated genes overlapped
with ST-EPN-RELA associated genes, while 67 of G16-4
(C11orf95-RELAfus1) up-regulated genes overlapped the
ST-EPN-RELA associated gene list, including some wellknown marker genes such as L1CAM, CHD5 and NOTCH1
(Supplementary Fig. 4a, b, online resource). All these
observations collectively indicate that C
 11orf95fus1 alone
is not sufficient to drive transcriptomic dysregulation like
C11orf95-RELAfus1.
While the HEK293T transgenic cell models allow the
dissection of the molecular function of C11orf95-RELA
and its constituents, to obtain insights of the epigenomic
and transcriptomic effects of C11orf95-RELA in the context of ependymoma, we performed further experiments in
an ependymoma cell line, BXD-1425-EPN [19] that was
established from an orthotopic patient-derived xenograft
(PDX) originating from a ST-EPN-RELA tumor. Genotyping-sequencing and Western blot experiments with BXD1425-EPN identified a novel fusion configuration containing the first three exons and a small fragment of the fourth
exon of C11orf95 gene, and RELA without the first two
and half exons (Supplementary Fig. 3c, online resource),
here referred to as C11orf95-RELA1425. Despite the lack of
fusion-specific antibody, the fact that unstimulated RELA
is excluded from the nucleus [5] while the fusion protein
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binds to DNA allowed us to use anti-RELA antibody to
conduct ChIP-seq to pull down C11orf95-RELA1425 bound
chromatin. RELA ChIP-seq in BXD-1425-EPN cells identified 13,954 chromatin binding sites of C11orf95-RELA1425,
with 5,338 commonly shared by C11orf95-RELAfus1 bindings in G16-4 cells. With the binding peak sequences of
C11orf95fus1, C11orf95-RELAfus1 and C11orf-RELA1425,
we implemented de novo motif discovery using MEMEChIP tool [8]. An identical GC-rich motif (GTGGCCCC)
was readily recovered with top scores from all three sets of
ChIP-seq peak sequences (Fig. 2a), supporting the validity
of fusion protein pull-down by RELA antibody in BXD1425-EPN cells and further confirming that the C11orf95fus1
fragment dictates DNA binding specificity of the fusion
protein. As the motif consensus was repeatedly enriched by
using different cells with different types of C11orf95-RELA
fusion and different antibodies, the identified C11orf95 binding specificity is highly faithful. To establish GTGGCC
CC as the bona fide DNA binding motif of C11orf95, we
performed a reporter assay with 15 copies of GTGGCC
CC and a minimum promoter cloned upstream of an EGFP
reporter gene (Fig. 2b). As expected, C11orf95-RELAfus1
activated EGFP reporter expression harboring copies of
the putative C11orf95 motif. On the contrary, the unfused
constituents RELA or C
 11orf95fus1 were unable to activate
the reporter. Furthermore, supplementing C
 11orf95fus1
with a heterologous VP64 activation domain in the form
of C11orf95fus1-VP64 fusion endowed transactivation activity on the reporter with 15 copies of the putative C11orf95
(GTGGCCCC) DNA binding motif but not on a control
reporter harboring 15 copies of an unrelated USF1 motif.
These results suggest that C11orf95fus1 binds to the GC-rich
motif GTGGCCCC and may activate gene expression by
hijacking the transcriptional activation domain of RELA,
as in the case of the C11orf95-RELA fusion. Furthermore,
to examine the functional region of C11orf95fus1, we constructed three truncation mutants of C11orf95fus1-VP64
fusions and performed reporter assay to measure their transactivation activities (Supplementary Fig. 5, online resource).
Deletion of the zinc finger (ZF) domain led to the loss of
transactivation activity. In addition, deletion of the N-terminal and C-terminal regions upstream and downstream of
the ZF domain also resulted in the loss of transactivation
activity (Supplementary Fig. 5, online resource), suggesting
C11orf95fus1 might be the minimal fragment of C11orf95
required for DNA binding. These results and the observation
by Parker et al. [14] that C11orf95fus1 is the most frequent
breakpoint of C11orf95 and is contained in all identified
C11orf95-RELA fusion subtypes prompted us to speculate
that C11orf95fus1 is the minimal fragment required for a
functional C11orf95-RELA fusion.
Among the top-scoring ChIP-seq peaks of C11orf95RELAfus1 and C11orf95-RELA1425, approximately half of
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Fig. 2  a DNA binding motifs enriched for C
11orf95fus1 and
fus1
1425
C11orf95-RELA
and C11orf95-RELA
in G16-3, G16-4 and
BXD-1425-EPN cells, respectively. b Reporter assay. Reporter EGFP
gene was linked to identified C11orf95 binding motif as well as USF1
motif as control. Empty vector (EV), C11orf95-RELAfus1, RELA,
C11orf95fus1 or activation domain VP64 fused C
 11orf95fus1 were

expressed to test EGFP expression. EGFP signals were measured by
flow cytometry. c C11orf95 binding motif distribution in C11orf95RELA peaks in G16-4 and BXD-1425-EPN cells. d RELA,
C11orf95fus1, C11orf95-RELAfus1 and C11orf95-RELA1425 binding
profiles at C11orf95 and RELA genes. The orange bars indicate the
regions that have C11orf95 binding motifs

them contain one or more of the C11orf95 DNA binding motif
(Fig. 2c), implying a direct binding by the fusion protein. The
no-motif peaks might be bound by a C11orf95-RELA-containing protein complex that uses another pioneer subunit to initiate chromatin binding. Both motif and no-motif peaks were
distributed at either promoter or non-promoter region with no
significant bias (Fig. 2c). Interestingly, ChIP-seq experiments
in G16-4 and BXD-1425-EPN cells identified fusion binding peaks at C11orf95 promoter and RELA transcription end
sites, with the C11orf95 DNA binding motif observed in both
peaks (Fig. 2d), suggesting the possibility of auto-regulation.
To evaluate such hypothesis, we determined whether expression of endogenous C11orf95 in G16-4 cells was induced by
exogenous C11orf95-RELAfus1 provided by the transgene. The
alternative codon usage adopted in the C11orf95fus1 transgene
construction allowed us to encode the same C11orf95fus1 protein sequence with synonymous codons for distinguishing
sequencing reads derived from transgenic and endogenous
C11orf95 in RNA-seq experiments (Supplementary Fig. 1,
online resource). A two-fold up-regulation of endogenous
C11orf95 transcripts was observed in G16-4 but not in G16-3
cells after doxycycline induction, validating the potential of
C11orf95-RELA to positively auto-regulate its expression via
binding to the C11orf95 promoter (Supplementary Fig. 4b,
online resource).

C11orf95‑RELA modulates chromatin state
and mediates chromatin interaction
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We applied H3K27ac ChIP-seq to profile active chromatin
regions in HEK293T transgenic cell models and BXD-1425EPN to address the correlation between the fusion protein
binding and chromatin state. At 3,792 fusion protein binding
sites with top confidence in BXD-1425-EPN cells, strong
H3K27ac signals were observed (Fig. 3a). Comparative analysis of genome-wide H3K27ac profiles between transgenic
HEK293T cell models expressing fusion (G16-4) and RELA
(G16-2) identified 441 differential H3K27ac peaks specific
in G16-4 cells. These G16-4 specific H3K27ac peaks highly
correlated with fusion protein binding (Fig. 3b) with over
90% of them overlapping with fusion protein binding sites,
implying the C11orf95-RELA was able to initiate chromatin
state changes. CCND1 and L1CAM, two well-known marker
genes of ST-EPN-RELA, exemplify two different chromatin state outcomes upon fusion protein binding. At L1CAM
promoter region, fusion protein binding likely resulted in
the deposition of H3K27ac marks (Fig. 3c). On the contrary,
CCND1 promoter retained its active chromatin state regardless of the presence (in G16-4 and BXD-1425-EPN cells)
or absence (in G16-2 and G16-3 cells) of the fusion protein
binding (Fig. 3c).
As three-dimensional chromatin structure is known to be
tightly associated with disease and cancer development, we
next sought to identify changes in genome structure mediated by the fusion in ST-EPN-RELA. We utilized a sequencing-based chromatin capture approach HiC Chromatin
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Fig. 3  a ChIP-seq read densities of C11orf95-RELA1425 and
H3K27ac in BXD-1425-EPN cells. 3792 top-scoring C11orf94RELA1425 ChIP-seq peaks were used to plot the heatmap. The left
side heatmap showed C11orf95-RELA1425 signals along a 5 kb region
centering the peak summit. The right side heatmap showed H3K27ac
signals along the same regions. b Read densities of H3K27ac and
C11orf95-RELAfus1 in G16-4 cells. 441 differential H3K27ac peaks

in G16-4 compared to G16-2 cells were used to plot the heatmap.
The left side heatmap showed H3K27ac signals along a 5 kb region
centered with H3K27ac peak center. The right side heatmap showed
C11orf95-RELAfus1 signals along the same regions. c RELA,
C11orf95fus1, C11orf95-RELAfus1 and C11orf95-RELA1425 as well as
corresponding H3K27ac ChIP-seq profiles at ST-EPN-RELA marker
genes CCND1 and L1CAM

Immunoprecipitation (HiChIP) [10] to characterize genomewide chromatin interactions and connect the protein binding
peaks into loops and networks. We used anti-HA antibody
to perform HiChIP of HA-tagged fusion protein in G16-4
cell lines. By further filtering with C11orf95-RELAfus1-HA
ChIP-seq peaks, we identified a total of 32,669 high-confidence interactions. For BXD-1425-EPN cells, we performed
H3K27ac HiChIP and identified 15,777 C11orf95-RELA1425
mediated interactions filtered by both H3K27ac and RELA
ChIP-seq peaks. We mapped HiChIP identified chromatin
interactions to the promoter regions of 886 ST-EPN-RELA
associated genes mentioned above (Supplementary Table 2,
online resource) to identify ST-EPN-RELA gene associated
interactions. As a result, a total of 445 common interactions were identified in both G16-4 and BXD-1425-EPN
cells. Interestingly, not all the 886 genes harbored chromatin interaction(s) to other locus/loci, but only 156 of them
(Supplementary Table 3, online resource) reached out to
one or more promoter or non-promoter (enhancer) regions.
Since these ST-EPN-RELA gene associated chromatin interactions were directly mediated by the fusion protein, it is
reasonable to speculate that the more interacting partners
one gene has, the more regulatory events it is involved in,
and the more important roles it plays in ST-EPN-RELA.
In other words, the genes that have more interactions with
other genomic loci are more likely to be the hub of the fusion
protein mediated network and more delicately regulated in
fusion-associated transcription, so that they might contribute more to ependymoma development. Hence, we counted
the number of interactions each gene promoter is involved
in and plotted a histogram ranking the 156 genes by their

interaction counts (Fig. 4a). The top-ranking genes included
CACNA1H, MAFG, NOTCH1, GPSM1, MXRA8, PYCR1,
VWA1 and RXRA. Of note, CACNA1H is a calcium channel
gene previously implicated and experimentally validated to
be important in ST-EPN-RELA cell survival [9], supporting the validity of our strategy in grading the significance
of the genes. NOTCH1 and GPSM1 encode membrane proteins critical for Notch signaling and G-protein signaling,
respectively, suggesting the involvement of these signaling pathways in ependymoma development in addition to
NF-κB pathway that has received the most attention. To
comprehensively nominate ependymoma-associated signaling pathways, we conducted a canonical pathway analysis
with the genes that have more than one interacting chromatin
site using Ingenuity Pathway Analysis (Qiagen) (Fig. 4b).
Interestingly, the top enriched pathway was Notch signaling. Looking back at the ST-EPN-RELA gene list (Supplementary Table 2, online resource), 15 Notch signaling genes
stood out, ADAM12, CCND1, DLK1, DVL1, DVL2, HDAC1,
HES1, HES5, JAG1, JAG2, LFNG, LNX1, MFAP2, NOTCH1
and PSENEN, further demonstrating Notch signaling might
play a significant role in ST-EPN-RELA oncogenesis [2].
As we mentioned above, the fusion protein not only
mediates promoter-promoter interactions but also enhancerpromoter interactions. To this end, we again made use of
the 445 ST-EPN-RELA gene associated chromatin interactions identified in both G16-4 and BXD-1425-EPN cells,
but focusing on the 91 non-promoter (putative enhancer)
regions (Supplementary Table 4, online resource). We then
counted the number of gene promoters connecting to these
91 enhancers. Although the majority of the enhancers had
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Fig. 4  a Histogram of interaction counts per gene. The interactions
coming out from the 156 identified gene promoters were counted.
b Canonical pathway analysis of 102 genes that had more than one
interaction. The numbers by the pathways are p values. c Chromatin
interactions captured by HiChIP along NOTCH1 and GPSM1 genes.

The heatmaps showed a 1 Mb region of interactions along NOTCH1
and GPSM1 genes. The browser view showed the zoom-in details of
the black box indicating region in the heatmaps, including ChIP-seq
profiles and HiChIP interactions. The green bars indicate NOTCH1
and GPSM1 promoters. The orange bar indicates the enhancer

only one interacting promoter, some of them interacted with
two to seven promoters (Supplementary Fig. 6a, online
resource). The enhancer with the highest number of promoter interactions is located in the intron of ASPSCR1 gene
on chromosome 17, connecting with ASPSCR1, DCXR,
MAFG, MAFG-AS1, NPB, PYCR1 and RAC3 genes (Supplementary Fig. 6b, online resource). More impressively,
another distal enhancer had robust interactions with promoters of NOTCH1 and GPSM1 genes in both G16-4 and
BXD-1425-EPN cells. Fusion protein binding was intensive
and resulted in H3K27ac deposition at the enhancer region
in G16-4 and BXD-1425-EPN cells (Fig. 4c). This suggests
a potential regulatory scenario in which the fusion protein
induces epigenetic changes at an enhancer and mediates
chromatin reorganization with key genes of two distinct
arms of signaling, specifically the Notch and G-protein
signaling pathways, to initiate genetic programs underlying
ST-EPN-RELA pathogenesis.

Discussion
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Informed by our study of epigenetic reprogramming driven
by C11orf95-RELA fusion in HEK293T cell models and
ependymoma cell line, we gained important knowledge
in the molecular mechanisms underlying tumorigenesis
driven by a single oncogenic C11orf95-RELA fusion [11,
14, 15]. Although the overexpression of C 11orf95 fus1
alone in HEK293T cells was not sufficient to drive ependymoma-like transcriptomic transformation, the ChIP-seq
with both HEK293T and BXD-1425-EPN cells shows
that the C11orf95 portion of the fusion plays a critical
role binding to DNA and thus serving as a shuttle for the
entry of RELA to the nucleus. By recognizing a specific
DNA motif, C11orf95 portion targets particular genes
and regulates their expression by hijacking the activation
domain of RELA. Other than RELA, there was indication that C11orf95 also fused to other transcription factors
such as YAP1 [12, 14] in ST-EPN-RELA, further implying the driving role of C11orf95. Since the first discovery
of C11orf95-RELA mutation in ST-EPN, NF-κB pathway caught the most attention in tumorigenesis signaling
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[14, 15]. However, it is not the only pathway involved in
ST-EPN-RELA [11]. Suggested by our chromatin interaction analysis in HEK293T and BXD-1425-EPN cell
models, Notch signaling ranked among the top pathways
involved in ST-EPN-RELA development, as a number of
Notch genes were identified as chromatin hubs harboring more than one distal interacting partners. However,
when we applied Notch inhibitor to treat BXD-1425-EPN
cells, no significant effect on cell survival and growth
was observed (data not shown). de Almeida Magalhães
T et al. also had the same observation in their study [2].
They claimed although Notch inhibitor treatment did not
change cell proliferation, apoptosis and colony formation
of ST-EPN-RELA, it induced down-regulation of cancer
stem cell markers. Therefore, we speculate on two possible
scenarios regarding the roles of Notch signaling. The first
possibility is that Notch signaling is not required for EPN
cell maintenance, though it is essential for EPN development, as other signaling pathways may play substitutional
roles such as the NF-κB and G-protein signaling pathways. Of note, NF-κB inhibitor alone did not change cell
viability in ST-EPN-RELA, either [4], suggesting perhaps
combinatorial treatment targeting multiple pathways could
be pursued for ST-EPN-RELA therapeutics. Another possibility is that the efficacy of Notch inhibitor treatment on
cell lines could be different from that of in vivo treatment
in mice or human, since the microenvironment might be
critical in determining the response of the cancer cells to
treatment. The roles of the Notch, NF-κB, and G-protein
pathways in EPN will warrant further in vivo investigations using single agent or combinations of inhibitors.
Another interesting finding of this study is that other than
the direct binding to gene promoters, C11orf95-RELA also
bind to regulatory elements such as enhancers by chromatin interaction analysis. The enhancers identified to
interact with multiple ST-EPN-RELA genes are potential
targets for therapeutic interventions. Specifically, by disrupting one particular enhancer, more than one ST-EPNRELA genes could be affected, providing a more efficient
way to manipulate gene expression in ependymoma. While
the present work presents the first epigenomic and transcriptomic characterization of the genetic program induced
by the C11orf95-RELA fusion protein, future works on
additional ST-EPN-RELA cell lines and primary tumors
will further establish the core program as well as subtype
differences critical for the development of precision and
personalized therapeutics for this devastating cancer.
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